Adebrelimab with chemotherapy for early esophageal cancer
Part of Cancer clinical trials.
This study tests a new immunotherapy drug called adebrelimab combined with standard chemotherapy before surgery for esophageal squamous cell carcinoma (a type of throat cancer). The goal is to shrink the tumor and improve outcomes before the surgical removal of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have esophageal squamous cell carcinoma (a specific type of throat cancer) that can be surgically removed and is at an advanced stage
- You have never received chemotherapy, radiation, or immunotherapy for esophageal cancer
- Your blood counts, liver, kidney, and heart function are healthy enough (as measured by blood tests and heart ultrasound)
- You do not have cancer that has spread to the brain or other organs beyond the esophagus and nearby lymph nodes
- You do not have an active autoimmune disease (like lupus, rheumatoid arthritis, or inflammatory bowel disease)
- You are willing to use birth control during the study and for 6 months after, and females must have a negative pregnancy test
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called adebrelimab given before surgery for esophageal cancer that can be removed. The goal is to see if it helps shrink the tumor and improve outcomes.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
This trial tests a combination of the immunotherapy drug adebrelimab (SHR-1316) and chemotherapy given before and after surgery for locally advanced esophageal squamous cell carcinoma that can be removed. The goal is to see if this approach helps shrink the tumor and improves outcomes.
This study tests a combination of two drugs (a type of immunotherapy called adebrelimab and an immune-boosting drug called thymalfasin) given with chemotherapy before surgery for esophageal cancer. The goal is to see if this approach can shrink the tumor and improve the chances of a successful surgery.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.